Compare CRAI & AVLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRAI | AVLN |
|---|---|---|
| Founded | 1965 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 1998 | 2026 |
| Metric | CRAI | AVLN |
|---|---|---|
| Price | $177.01 | $24.54 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 5 |
| Target Price | ★ $250.50 | $61.80 |
| AVG Volume (30 Days) | 88.9K | ★ 294.6K |
| Earning Date | 10-29-2026 | 11-25-2026 |
| Dividend Yield | ★ 1.30% | N/A |
| EPS Growth | ★ 20.77 | N/A |
| EPS | ★ 8.14 | N/A |
| Revenue | ★ $751,583,000.00 | N/A |
| Revenue This Year | $8.35 | N/A |
| Revenue Next Year | $4.01 | N/A |
| P/E Ratio | $21.57 | ★ N/A |
| Revenue Growth | ★ 9.33 | N/A |
| 52 Week Low | $132.17 | $22.68 |
| 52 Week High | $227.29 | $40.17 |
| Indicator | CRAI | AVLN |
|---|---|---|
| Relative Strength Index (RSI) | 61.44 | 32.78 |
| Support Level | $153.02 | N/A |
| Resistance Level | $194.00 | $30.45 |
| Average True Range (ATR) | 5.27 | 1.60 |
| MACD | 1.14 | -0.17 |
| Stochastic Oscillator | 84.14 | 31.17 |
CRA International Inc is a consulting firm specializing in providing economic, financial and management consulting services. The company provides advisory services on economic and financial matters related to litigation and regulatory proceedings, and advises corporations on business and performance-related matters. Its consulting services are organized into two areas: litigation, regulatory and financial consulting, and management consulting. The company's clients include domestic and foreign companies, government agencies, public and private utilities, and national and international trade associations. It derives revenues by providing professional and consulting services. Geographically, the maximum revenue is derived from the United States, followed by United Kingdom and other regions.
Avalyn Pharma Inc is a clinical-stage biopharmaceutical company developing inhaled medicines to treat rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases (ILDs). Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, which is a significantly shorter prognosis than that observed for many forms of cancer. Its flagship programs include AP01 and AP02, which are inhaled formulations of pirfenidone and nintedanib being developed for conditions such as progressive pulmonary fibrosis and idiopathic pulmonary fibrosis. The company has one operating and reportable segment, which is the business of developing and commercializing targeted therapies for rare lung diseases.